Zaleplon 10mg Capsules Under Fasting Conditions

Overview

The objective of this study was to compare the relative bioavailability of Zaleplon 10 mg Capsules manufactured by TEVA Pharmaceuticals USA and Sonata® 10 mg Capsules manufactured by Wyeth Laboratories in healthy, non-smoking adults under fasting conditions.

Full Title of Study: “A Relative Bioavailability Study of Zaleplon 10mg Capsules Under Fasting Conditions”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2004

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA bioequivalence statistical methods

Interventions

  • Drug: Zaleplon 10 mg Capsules
    • 1 x 10 mg, single-dose fasting
  • Drug: Sonata® 10 mg Capsules
    • 1 x 10 mg, single-dose fasting

Arms, Groups and Cohorts

  • Experimental: Zaleplon
    • Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
  • Active Comparator: Sonata®
    • Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period

Clinical Trial Outcome Measures

Primary Measures

  • Cmax – Maximum Observed Concentration
    • Time Frame: Blood samples collected over 10 hour period
    • Bioequivalence based on Cmax
  • AUC0-inf – Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
    • Time Frame: Blood samples collected over 10 hour period
    • Bioequivalence based on AUC0-inf
  • AUC0-t – Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
    • Time Frame: Blood samples collected over 10 hour period
    • Bioequivalence based on AUC0-t

Participating in This Clinical Trial

Inclusion Criteria

  • non-smokers – at least 18 years of age – BMI of 30 or less Exclusion Criteria:

  • Subjects with a significant recent history of chronic alcohol consumption (past 2 years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma (past 5 years), diabetes, psychosis or glaucoma will not be eligible for this study. – Subjects whose clinical laboratory test values are outside the reference ranges may be retested at the discretion of the clinical investigator. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant. – Subjects who have a history of allergic responses to the class of drug being tested will be excluded from the study. Subjects with intolerance to alcohol or other CNS depressants should not participate in this study. – Subjects who use tobacco in any form will not be eligible to participate in the study. Three months abstinence is required. – All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at each dosing period check-in. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate. – Subjects should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study. – Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate. – Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant during the study will not be allowed to participate. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or they will not be allowed to participate. Female subjects who have used hormonal oral contraceptives within 14 days of dosing or implanted or injected hormonal contraceptives within 180 days of dosing will not be allowed to participate. – All female subjects will be screened for pregnancy at check-in each study period. Subjects with positive or inconclusive results will be withdrawn from the study. – Subjects who do not tolerate venipuncture will not be allowed to participate.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Teva Pharmaceuticals USA
  • Overall Official(s)
    • So Ran Hong, M.D., Principal Investigator, Novum Pharmaceutical Research Services

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.